Allergan PLC. (AGN) Given a $231.00 Price Target by Cantor Fitzgerald Analysts

Cantor Fitzgerald set a $231.00 price objective on Allergan PLC. (NYSE:AGN) in a research report sent to investors on Thursday morning. The brokerage currently has a hold rating on the stock.

A number of other equities analysts have also issued reports on AGN. Cowen and Company reissued a buy rating on shares of Allergan PLC. in a research report on Thursday. Piper Jaffray Companies set a $227.00 price target on shares of Allergan PLC. and gave the stock a hold rating in a research report on Friday, October 6th. Wells Fargo & Company reissued a buy rating on shares of Allergan PLC. in a research report on Monday, October 2nd. Barclays PLC reissued an equal weight rating on shares of Allergan PLC. in a research report on Monday, October 2nd. Finally, UBS AG reissued a buy rating and set a $275.00 price target on shares of Allergan PLC. in a research report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $271.44.

Allergan PLC. (NYSE:AGN) traded up 0.71% on Thursday, hitting $205.52. 1,815,947 shares of the stock traded hands. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The company has a market capitalization of $68.71 billion, a PE ratio of 6.26 and a beta of 1.15. The firm has a 50-day moving average price of $216.44 and a 200-day moving average price of $232.29.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. Allergan PLC.’s revenue was up 8.8% on a year-over-year basis. During the same period last year, the firm posted $3.35 EPS. Analysts forecast that Allergan PLC. will post $16.21 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://ledgergazette.com/2017/10/13/allergan-plc-agn-given-a-231-00-price-target-by-cantor-fitzgerald-analysts.html.

Allergan PLC. announced that its board has initiated a share repurchase plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

The business also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were paid a $0.70 dividend. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.36%. Allergan PLC.’s dividend payout ratio is currently 9.95%.

A number of institutional investors have recently added to or reduced their stakes in the stock. Hudock Capital Group LLC grew its stake in Allergan PLC. by 0.4% in the 2nd quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock valued at $138,000 after acquiring an additional 2 shares during the period. GWM Advisors LLC boosted its stake in Allergan PLC. by 0.4% during the 1st quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after purchasing an additional 5 shares during the last quarter. Burns J W & Co. Inc. NY boosted its stake in Allergan PLC. by 0.7% during the 2nd quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after purchasing an additional 6 shares during the last quarter. Pacific Center for Financial Services boosted its stake in Allergan PLC. by 1.3% during the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after purchasing an additional 7 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC boosted its stake in Allergan PLC. by 0.5% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after purchasing an additional 9 shares during the last quarter. 82.04% of the stock is currently owned by hedge fu

A number of other equities analysts have also issued reports on AGN. Cowen and Company reissued a buy rating on shares of Allergan PLC. in a research report on Thursday. Piper Jaffray Companies set a $227.00 price target on shares of Allergan PLC. and gave the stock a hold rating in a research report on Friday, October 6th. Wells Fargo & Company reissued a buy rating on shares of Allergan PLC. in a research report on Monday, October 2nd. Barclays PLC reissued an equal weight rating on shares of Allergan PLC. in a research report on Monday, October 2nd. Finally, UBS AG reissued a buy rating and set a $275.00 price target on shares of Allergan PLC. in a research report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $271.44.

Allergan PLC. (NYSE:AGN) traded up 0.71% on Thursday, hitting $205.52. 1,815,947 shares of the stock traded hands. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The company has a market capitalization of $68.71 billion, a PE ratio of 6.26 and a beta of 1.15. The firm has a 50-day moving average price of $216.44 and a 200-day moving average price of $232.29.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. Allergan PLC.’s revenue was up 8.8% on a year-over-year basis. During the same period last year, the firm posted $3.35 EPS. Analysts forecast that Allergan PLC. will post $16.21 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://ledgergazette.com/2017/10/13/allergan-plc-agn-given-a-231-00-price-target-by-cantor-fitzgerald-analysts.html.

Allergan PLC. announced that its board has initiated a share repurchase plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

The business also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were paid a $0.70 dividend. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.36%. Allergan PLC.’s dividend payout ratio is currently 9.95%.

A number of institutional investors have recently added to or reduced their stakes in the stock. Hudock Capital Group LLC grew its stake in Allergan PLC. by 0.4% in the 2nd quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock valued at $138,000 after acquiring an additional 2 shares during the period. GWM Advisors LLC boosted its stake in Allergan PLC. by 0.4% during the 1st quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after purchasing an additional 5 shares during the last quarter. Burns J W & Co. Inc. NY boosted its stake in Allergan PLC. by 0.7% during the 2nd quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after purchasing an additional 6 shares during the last quarter. Pacific Center for Financial Services boosted its stake in Allergan PLC. by 1.3% during the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after purchasing an additional 7 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC boosted its stake in Allergan PLC. by 0.5% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after purchasing an additional 9 shares during the last quarter. 82.04% of the stock is currently owned by hedge funds and other institutional investors.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply